studi
evalu
antireoviru
activ
kuraridin
isol
root
sophora
flavescen
particular
focus
whether
properti
attribut
direct
inhibit
reoviru
attach
andor
inhibit
viral
replic
aid
timeofaddit
pretreat
simultan
treatment
posttreat
experi
signific
antivir
activ
kuraridin
detect
pretreat
assay
simultan
assay
effect
inhibitori
concentr
ec
kuraridin
mm
human
type
reovirus
korean
porcin
reoviru
prv
kuraridin
complet
block
bind
viral
sigma
protein
sialic
acid
concentr
lower
mm
hemagglutin
inhibit
assay
moreov
kuraridin
inhibit
prv
viral
replic
ec
valu
mm
quantit
realtim
pcr
analysi
disclos
strong
suppress
reoviru
rna
synthesi
late
stage
h
viru
replic
kuraridin
viral
yield
kuraridintr
cell
significantli
reduc
h
postinfect
compar
dmsotreat
cell
result
collect
suggest
kuraridin
inhibit
viru
adsorpt
replic
inhibit
hemagglutin
viral
rna
protein
synthesi
viru
shed
support
util
viabl
candid
antivir
drug
reovirus
mammalian
reoviru
mrv
prototyp
member
reovirida
famili
nonenvelop
doublestrand
rna
dsrna
virus
genom
compos
ten
segment
reovirus
origin
refer
respiratori
enter
orphan
first
isol
human
unit
state
mexico
mrv
repres
four
prototyp
strain
type
lang
type
jone
type
dear
type
ndell
major
strain
assign
serogroup
reovirus
isol
respiratori
enter
tract
children
mild
respiratori
gastrointestin
symptom
howev
limit
studi
focus
human
reovirusassoci
neurolog
diseas
date
pneumonia
respiratori
diseas
natur
experiment
infect
primat
isol
reovirus
children
mening
enceph
wide
document
mrv
infect
wide
rang
host
includ
livestock
pig
cattl
chicken
contribut
sever
econom
loss
worldwid
use
antivir
agent
commonplac
toxic
high
product
cost
henc
effect
inexpens
altern
antivir
drug
remain
urgent
unmet
medic
need
mani
tradit
medicin
plant
display
strong
antivir
activ
util
success
treatment
infect
anim
human
demonstr
life
cycl
virus
divid
sever
stage
includ
cell
surfac
attach
penetr
uncoat
replic
protein
synthesi
releas
provid
target
antivir
agent
current
antivir
drug
licens
treatment
human
immunodefici
viru
hiv
hepat
b
viru
hbv
herpesvirus
howev
number
licens
antivir
drug
treatment
highli
pathogen
rna
viru
infect
remain
limit
viral
diseas
consid
difficult
treat
select
antivir
chemotherapi
highlight
need
refin
antivir
drug
design
develop
medicin
plant
varieti
chemic
constitu
includ
alkaloid
tannin
saponin
flavonoid
terpenoid
lignan
coumarin
known
inhibit
replic
cycl
variou
dna
rna
viru
type
compound
deriv
natur
sourc
therefor
signific
interest
possibl
sourc
viral
infect
control
dri
root
sophora
flavescen
ait
flavescen
histor
use
tradit
chines
herbal
medicin
owe
antiinflammatori
antiarrhythm
antipyret
antiasthmat
antiulc
effect
treatment
diarrhea
gastrointestin
hemorrhag
eczema
addit
formul
contain
flavescen
report
inhibit
angiogenesi
collageninduc
arthriti
rat
model
previou
studi
quinolizidin
alkaloid
flavonoid
triterpenoid
isol
root
flavescen
recent
quinolizidin
alkaloid
flavonoid
shown
exhibit
wide
spectrum
pharmacolog
activ
includ
anticanc
antiinflammatori
antitumor
cardioprotect
neuroprotect
antibacteri
antiinfluenza
properti
howev
potenti
antireoviru
activ
extract
compound
isol
flavescen
examin
date
current
investig
evalu
abil
meoh
extract
etoac
fraction
kuraridin
isol
flavescen
inhibit
human
type
reovirus
korean
porcin
reoviru
prv
antivir
assay
employ
determin
whether
flavescen
compound
alter
reoviru
activ
inhibit
viru
attach
andor
replic
h
nmr
mhz
c
nmr
mhz
spectra
obtain
jeol
spectromet
cd
od
solvent
esim
determin
use
agil
lcmsm
lcm
spectromet
reversedphas
cc
carri
use
silica
gel
cosmosil
mm
nacalai
tesqu
inc
silica
gel
cc
conduct
use
kieselgel
mesh
merck
tlc
conduct
use
kieselgel
plate
merck
flavescen
purchas
herbal
market
jeongeup
korea
voucher
specimen
deposit
korea
plant
extract
bank
korea
research
institut
bioscienc
biotechnolog
dri
root
flavescen
kg
extract
meoh
l
day
room
temperatur
meoh
extract
evapor
vacuo
yield
residu
g
residu
suspend
distil
water
l
extract
nhexan
chcl
etoac
buoh
process
nhexan
g
chcl
g
etoac
g
buoh
g
layer
obtain
respect
etoac
layer
submit
open
column
chromatographi
silica
gel
mesh
g
fetal
rhesu
monkey
kidney
cell
grown
eagl
minimum
essenti
medium
emem
supplement
fetal
bovin
serum
fb
uml
penicillin
mgml
streptomycin
uml
amphotericin
b
cell
maintain
c
co
antibiot
trypsinedta
fb
emem
suppli
gibco
brl
grand
island
ny
usa
reoviru
type
lang
atcc
type
jone
atcc
type
dear
atcc
purchas
american
type
cultur
collect
atcc
prv
strain
isol
fecal
sampl
korean
diarrheic
piglet
use
studi
reovirus
preactiv
mgml
trypsin
gibco
invitrogen
corpor
ca
usa
min
c
inocul
onto
confluent
cell
infect
cell
maintain
presenc
mgml
trypsin
gibco
invitrogen
corpor
ca
usa
cell
grown
well
plate
cellswel
h
media
plate
replac
media
contain
serial
dilut
meoh
extract
etoac
fraction
mgml
kuraridin
mm
incub
h
h
solut
replac
media
ml
mtt
bromid
sigma
solut
ad
well
incub
c
h
remov
supernat
ml
hclisopropanol
ad
solubil
formazan
crystal
absorb
measur
nm
subtract
background
measur
nm
use
micropl
reader
cell
viabil
calcul
percentag
total
number
dmsotreat
control
cell
cc
calcul
describ
antivir
assay
previous
describ
visual
assay
perform
neutral
red
method
briefli
describ
pretreat
assay
fig
cell
grown
well
plate
cellswel
h
viru
inocul
noncytotox
concentr
cc
meoh
extract
etoac
fraction
kuraridin
isol
flavescen
ad
cell
incub
h
extract
compound
remov
cell
wash
time
pb
reovirus
multipl
infect
moi
inocul
onto
cell
h
occasion
rock
media
remov
replac
emem
contain
mgml
trypsin
cultur
incub
h
c
co
atmospher
cell
infect
untreat
control
well
show
complet
viral
cytopath
effect
cpe
observ
light
microscopi
concentr
extract
compound
assay
triplic
h
incub
antivir
assay
neutral
red
ad
well
incub
h
c
dark
neutral
red
solut
remov
cell
wash
pb
ph
destain
solut
contain
glacial
acet
acid
h
ethanol
ad
well
plate
incub
dark
min
room
temperatur
absorb
read
nm
use
micropl
reader
ec
defin
concentr
offer
inhibit
viral
yield
cell
calcul
describ
simultan
treatment
assay
fig
variou
concentr
meoh
extract
etoac
fraction
kuraridin
mix
viru
moi
incub
c
h
mixtur
inocul
onto
near
confluent
cell
monolay
cellswel
h
occasion
rock
solut
remov
media
replac
cultur
incub
h
c
co
atmospher
cell
infect
untreat
control
well
show
complet
viral
cpe
observ
light
microscopi
concentr
extract
compound
assay
triplic
tabl
antivir
activ
meoh
extract
etoac
fraction
kuraridin
isol
flavescen
reoviru
simultaneousand
posttreat
assay
extract
compound
post
treatment
assay
fig
reovirus
moi
inocul
onto
near
confluent
cell
monolay
cellswel
h
occasion
rock
media
remov
replac
emem
meoh
extract
etoac
fraction
kuraridin
differ
concentr
cultur
incub
h
c
co
atmospher
cell
infect
untreat
control
well
show
complet
viral
cpe
observ
light
microscopi
concentr
extract
compound
assay
viru
inhibit
triplic
hemagglutin
inhibit
assay
perform
evalu
effect
meoh
extract
etoac
fraction
kuraridin
viral
adsorpt
target
cell
reovirus
solut
hau
ml
mix
equal
volum
extract
compound
ml
twofold
serial
dilut
pb
ph
h
c
prepar
solut
ml
mix
equal
volum
human
red
blood
cell
hrbc
type
bovin
red
blood
cell
brbc
prv
suspens
incub
h
room
temperatur
total
rna
revers
transcrib
cdna
use
high
capac
rnatocdna
master
mix
appli
biosystem
accord
manufactur
instruct
revers
transcript
perform
c
h
enzym
inactiv
c
min
cdna
store
c
directli
use
quantit
realtim
pcr
realtim
pcr
conduct
use
ml
cdna
power
sybr
green
pcr
master
mix
appli
biosystem
cycl
condit
realtim
pcr
follow
c
min
follow
cycl
c
c
realtim
pcr
conduct
use
step
one
plu
realtim
pcr
system
data
analyz
stepon
softwar
appli
biosystem
cell
infect
prv
strain
moi
plate
h
viru
adsorpt
c
cell
wash
three
time
pb
cultur
medium
contain
meoh
extract
etoac
fraction
mgml
kuraridin
differ
concentr
untreat
cell
viru
control
dmso
includ
supernat
harvest
h
viru
yield
determin
use
plaqu
assay
day
determin
perform
thrice
triplic
experi
repeat
least
three
time
differ
group
assess
use
oneway
twoway
anova
follow
tuckey
posthoc
analysi
data
present
mean
anova
combin
standard
error
mean
sem
valu
p
consid
signific
compar
untreat
control
cell
viabil
cultur
treat
two
extract
kuraridin
evalu
use
mtt
assay
fig
cc
cytotox
concentr
valu
meoh
extract
etoac
fraction
mgml
respect
kuraridin
consider
lower
mm
tabl
accordingli
experi
evalu
antivir
effect
perform
concentr
minim
toxic
mgml
meoh
extract
etoac
fraction
mm
kuraridin
pretreat
assay
perform
examin
inhibitori
effect
two
extract
kuraridin
reoviru
attach
host
cell
fig
simultan
treatment
assay
addit
conduct
determin
whether
extract
kuraridin
directli
inhibit
reoviru
particl
fig
pretreat
assay
meoh
extract
etoac
fraction
kuraridin
show
inhibitori
effect
prv
data
shown
notabl
howev
simultan
treatment
assay
two
extract
inhibit
reoviru
entri
fig
meoh
extract
etoac
fraction
exhibit
decreas
order
antivir
activ
prv
kuraridin
exhibit
antivir
activ
decreas
order
prv
tabl
interestingli
data
indic
extract
kuraridin
exert
stronger
inhibitori
effect
prv
greatest
inhibitori
effect
kuraridin
prv
isol
korean
porcin
diarrheic
fece
simultan
treatment
assay
establish
either
viru
adsorpt
cell
entri
inhibit
two
extract
kuraridin
accordingli
evalu
whether
extract
kuraridin
inhibit
reovirusinduc
hemagglutin
bind
hrbc
prv
brbc
meoh
extract
etoac
fraction
complet
inhibit
attach
hrbc
well
prv
attach
brbc
concentr
less
mgml
fig
decreas
order
hi
activ
follow
prv
meoh
extract
prv
etoac
fraction
kuraridin
exhibit
similar
decreas
order
hi
activ
prv
overal
meoh
extract
etoac
fraction
kuraridin
show
stronger
hi
activ
prv
consist
find
simultan
assay
result
clearli
indic
strong
interact
two
extract
kuraridin
hemagglutinin
outerlay
protein
sigma
reoviru
result
inhibit
viral
attach
posttreat
assay
perform
evalu
inhibitori
effect
meoh
extract
etoac
fraction
kuraridin
reoviru
replic
fig
meoh
extract
etoac
fraction
inhibit
viral
replic
preliminari
experi
fig
decreas
order
activ
prv
tabl
kuraridin
exert
decreas
antivir
activ
follow
order
prv
tabl
similar
result
simultan
treatment
assay
three
isol
fraction
show
stronger
inhibitori
effect
prv
viral
rna
level
synthes
earli
late
stage
viru
infect
compar
kuraridintr
number
fluoresc
cell
infect
prv
fig
determin
effect
two
extract
kuraridin
reoviru
product
perform
viru
yield
reduct
assay
viral
yield
estim
use
plaqu
assay
notabl
meoh
extract
etoac
fraction
kuraridin
suppress
product
prv
dosedepend
manner
indic
inhibit
reoviru
shed
releas
fig
variou
step
viral
replic
cycl
target
antivir
agent
includ
adsorpt
cell
penetr
uncoat
transcript
translat
assembl
viral
releas
infect
cell
hypothes
antivir
effect
flavescen
divid
two
step
blockag
viru
adsorpt
cell
inhibit
viral
replic
cell
entri
timeofaddit
experi
perform
determin
stage
inhibitori
activ
exert
meoh
extract
etoac
fraction
kuraridin
flavescen
ad
cell
three
distinct
timepoint
specif
prior
infect
pretreat
time
viru
infect
simultan
postinfect
posttreat
fig
reoviru
entri
cell
multistep
process
involv
sever
interact
outer
layer
protein
sigma
protein
cell
surfac
receptor
includ
sialic
acid
sa
junction
adhes
moleculea
jama
sigma
protein
specifi
tissu
tropism
respons
hemagglutin
ha
activ
bind
sa
ha
activ
reovirus
strongli
impli
role
sa
cell
bind
infect
reovirus
similar
influenza
viru
rotaviru
variou
coronavirus
sendai
viru
current
studi
hi
assay
employ
assess
inhibitori
effect
extract
kuraridin
viral
adsorpt
host
cell
meoh
extract
etoac
fraction
complet
inhibit
adsorpt
hrbc
well
prv
adsorpt
brbc
concentr
mgml
kuraridin
induc
complet
inhibit
hemagglutin
activ
hrbc
prv
brbc
concentr
mm
fig
hi
activ
kuraridin
stronger
prv
differ
link
sigma
protein
sequenc
possibl
attribut
serotypespecif
interact
viral
protein
differ
cell
surfac
receptor
five
residu
sigma
protein
report
play
role
reoviru
sa
interact
addit
sa
bind
sigma
protein
type
reoviru
mediat
eightstrand
cross
bsheet
iii
domain
residu
hemagglutin
type
reoviru
mediat
iii
iv
domain
residu
thu
divers
sigma
protein
accord
type
fig
reduct
reoviru
product
meoh
extract
etoac
fraction
kuraridin
cell
infect
prv
moi
treat
dmso
meoh
extract
mgml
etoac
fraction
mgml
b
kuraridin
mm
c
h
supernat
fraction
harvest
viru
titer
determin
plaqu
assay
data
express
mean
anova
combin
standard
error
three
independ
assay
p
compar
dmsotreat
cell
use
control
serotyp
may
influenc
interact
kuraridin
hemagglutinin
protein
hi
assay
result
agreement
simultan
treatment
assay
tabl
indic
extract
kuraridin
potenti
exert
antireovir
activ
via
blockag
viral
attach
sa
host
cell
surfac
inhibit
viru
attach
turn
prevent
viru
entri
replic
occurr
infect
extract
kuraridin
significantli
inhibit
reoviru
replic
infect
dosedepend
manner
posttreat
assay
fig
although
mechan
kuraridin
inhibit
reoviru
replic
current
unclear
compound
known
affect
viral
factor
rna
protein
experi
show
viral
rna
level
significantli
lower
kuraridin
interestingli
reovir
rna
synthesi
significantli
inhibit
kuraridin
late
stage
h
viral
replic
cycl
prv
fig
reoviru
replic
cycl
compris
two
distinct
transcript
phase
primari
secondari
occur
earli
late
stage
respect
primari
transcript
viral
rna
rapidli
replic
h
postinfect
within
progeni
viral
particl
secondari
transcript
mediat
particl
assembl
newli
synthes
rna
protein
molecul
matur
virion
produc
h
postinfect
find
indic
kuraridin
inhibit
viral
protein
synthesi
sigma
produc
chang
viral
rna
level
reduc
viru
shed
fig
base
result
suggest
kuraridin
suppress
reoviru
replic
via
inhibit
viral
rna
protein
synthesi
viru
releas
ribavirin
report
exert
antireoviru
activ
inhibit
viral
multipl
number
natur
product
extens
investig
antivir
virucid
activ
gallat
deriv
display
antivir
effect
use
antioxid
food
addit
includ
propyl
gallat
octyl
gallat
lauryl
gallat
mycophenol
acid
addit
identifi
antireovir
agent
act
revers
inhibitor
eukaryot
imp
dehydrogenas
impdh
anoth
studi
demonstr
chestnut
quebracho
wood
extract
contain
tannin
show
antivir
activ
avian
reoviru
metapneumoviru
dipeptid
benzyloxycarbonylphealafluoromethyl
keton
zfafmk
novel
potent
inhibitor
reoviru
pathogenesi
oncolysi
vivo
drug
act
inhibit
reoviru
replic
adsorpt
potenti
sideeffect
yet
clinic
evalu
natur
product
may
ideal
candid
sinc
less
toxic
effect
fewer
sideeffect
less
expens
commerci
avail
antireoviru
agent
result
current
studi
collect
indic
compound
isol
flavescen
may
superior
antireoviru
agent
highlight
medic
import
identifi
effect
natur
antivir
agent
none
